ADAM12 and cancer: The expression level of ADAM12 was negatively correlated with the response to 20 anti-cancer drugs, inclu-ding the tyrosine kinase inhibitors Imatinib and Pazopanib (r = − 0.701 and − 0.598, respectively), the angiokinase inhibitor AMG.706 (r = − 0.626), the mitosis inhibitor Docetaxel (r = − 0.553), and Cisplatin, which interferes with DNA replication (r = − 0.531).